The beaten down biotech sector may offer more opportunities in this newly volatile market environment.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
TheStreet's founder Jim Cramer and a panel of top experts discuss how investors should be positioning their portfolio for March in this month's Trading Strategies session. In this clip above, listen to them discuss healthcare stocks and why they think they're too hard to trade.
Here's what you need to know now for Monday, March 5.
These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.
Jim Cramer questions whether Celgene overpaid in its $7.2 billion deal for Receptos.
Johnson & Johnson may be down, but don't count it out.
The Food and Drug Administration determined that the nonclinical and clinical pharmacology sections in the new drug application "were insufficient to permit a complete review," Celgene said.
Representing a change from a year ago, large-cap healthcare firms are now attractively valued compared to the broader stock market, according to RBC Capital Markets' Lori Calvasina.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.